Relation of Incident Type 1 Diabetes to Recent COVID-19 Infection: Cohort Study Using e-Health Record Linkage in Scotland
CONCLUSIONSType 1 diabetes incidence in children increased during the pandemic. However, the cohort analysis suggests that SARS-CoV-2 infection itself was not the cause of this increase. (Source: Diabetes Care)
Source: Diabetes Care - May 18, 2023 Category: Endocrinology Source Type: research
Phenotypes Associated With Zones Defined by Area Under the Curve Glucose and C-peptide in a Population With Islet Autoantibodies
CONCLUSIONSPhenotypes of 25 zones formed from AUCGLU and AUCPEP were used to gain insights into type 1 diabetes heterogeneity. Zones were used to examine GCRC changes with increasing AUCGLU, associations between risk and autoantibody prevalence, the dependence of glucose as a predictor of risk according to C-peptide, and glucose heterogeneity from contributions of insulin secretion and insulin resistance. (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
People With Type 1 Diabetes of African Caribbean Ethnicity Are at Increased Risk of Developing Sight-Threatening Diabetic Retinopathy
CONCLUSIONSWe observed that people with type 1 diabetes of African Caribbean ethnicity are at significantly greater risk of STDR. Further research is required to understand the mechanisms that explain this novel observation. (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Comment on Celis-Morales et al. Type 2 Diabetes, Glycemic Control, and Their Association With Dementia and Its Major Subtypes: Findings From the Swedish National Diabetes Register. Diabetes Care 2022;45:634 –641
The risk for Alzheimer disease was lower in patients with type 2 diabetes than in control subjects (hazard ratio 0.94 [95% CI 0.90, 0.99]) but might result in patients with type 2 diabetes dying earlier than control subjects, which was observed by Celis-Morales et al. (1) in a real-world prospective cohort with a large sample of individuals with type 2 diabetes and 7-year follow-up. We recommend that authors incorporate the death event as a competing risk in the Cox regression, which might clarify whether or to what extent type 2 diabetes contributes to the incident Alzheimer disease. (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Socioeconomic Disparities Across the Spectrum of Genetic Burden in Type 2 Diabetes and Obesity Risk
European Research CouncilCoG-2015_681742_NASCENT (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Response to Comment on Galvez-Fernandez et al. Urinary Zinc and Incident Type 2 Diabetes: Prospective Evidence From the Strong Heart Study. Diabetes Care 2022;45:2561 –2569
National Heart, Lung, and Blood Institute10.13039/100000050U01HL4164275N92019D0002775N92019D0002875N92019D0002975N92019D00030R01HL090863R01HL109282R01HL109284R01HL109301R01HL109315R01HL109319U01HL41652U01HL41654U01HL65520U01HL65521National Institute of Environmental Health Sciences10.13039/100000066P30ES009089P42ES033719R01ES021367R01ES025216R01ES032638 (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Comment on Bezin et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023;46:384 –390
We read the article by Bezin et al. (1) with interest and would like to point out several flaws that make the interpretation unreliable. (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
About the Artist: Rohan Arora
(Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Metformin and Cancer: Solutions to a Real-World Evidence Failure
The quest to repurpose metformin, an antidiabetes drug, as an agent for cancer prevention and treatment, which began in 2005 with an observational study that reported a reduction in cancer incidence among metformin users, generated extensive experimental, observational, and clinical research. Experimental studies revealed that metformin has anticancer effects via various pathways, potentially inhibiting cancer cell proliferation. Concurrently, multiple nonrandomized observational studies reported remarkable reductions in cancer incidence and outcomes with metformin use. However, these studies were shown, in 2012, to be aff...
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Response to Comment on Celis-Morales et al. Type 2 Diabetes, Glycemic Control, and Their Association With Dementia and Its Major Subtypes: Findings From the Swedish National Diabetes Register. Diabetes Care 2022;45:634 –641
We appreciate the interest by Meng and Wang (1) in our article (2), which highlights the need to conduct a competing risk analysis between all-cause mortality, type 2 diabetes, and risk of Alzheimer disease, as the early average mortality experienced by patients with diabetes compared with controls could explain the inverse associations reported in our study. We completely agree; this is why our study already included all-cause mortality in competing risk analyses (2). As described in our methods and results section, the inverse association is indeed explained by the early mortality experienced in patients with diabetes co...
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Comment on Tang et al. The Impact of Carbamylation and Anemia on HbA 1c ’s Association With Renal Outcomes in Patients With Diabetes and Chronic Kidney Disease. Diabetes Care 2023;46:130–137
We were interested in the recent article inDiabetes Care from Tang et al. (1), in which they reported that lower HbA1c in subjects with highly carbamylated albumin (C-Alb) was not clearly related to glucose levels, precluding a relationship of HbA1c with the later progression of chronic kidney disease. (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Comment on Duarte et al. Systematic Review and Network Meta-analysis of Neurostimulation for Painful Diabetic Neuropathy. Diabetes Care 2022;45:2466 –2475
The benefits of spinal cord stimulation (SCS) for patients with painful diabetic peripheral neuropathy (DPN) have been well described in literature dating back decades. Recent U.S. Food and Drug Administration approvals have helped raise therapy visibility as an option for patients with refractory DPN. The accuracy of analyses is imperative in providing health care providers (HCPs) with the most informative guidance for treating patients with DPN. (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Comment on Galvez-Fernandez et al. Urinary Zinc and Incident Type 2 Diabetes: Prospective Evidence From the Strong Heart Study. Diabetes Care 2022;45:2561 –2569
We read with great interest the article by Galvez-Fernandez et al. (1) about the association of urinary zinc (UZn) (single exposure) with the risk of type 2 diabetes mellitus (T2DM) among 1,339 adults in the Strong Heart Study (SHS) and 1,905 family members of SHS participants in the Strong Heart Family Study (SHFS). The authors reported that higher UZn levels were statistically significantly associated with increased T2DM risk in the SHS cohort but not in the SHFS cohort. In the sensitivity analyses, the authors evaluated the association of UZn with T2DM risk by adjusting for urinary arsenic (UAs) and selenium (USe) lev...
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
COVID-19 and Rising Incidence of Diabetes: Despite Evolving Data, an Enigma Still to Be Solved
Since the start of the coronavirus disease 2019 (COVID-19) pandemic in 2020, the global scientific and medical communities have learned important lessons about this disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As the pandemic unfolded, we were informed about the major risk factors associated with the disease and had a heightened awareness of the disparities given that racial and ethnic minority groups were disproportionately affected (1,2). We witnessed incredible and rapid progress for research advances that led to improved management strategies and development of innovative therapeutics...
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
Comment on Duarte et al. Systematic Review and Network Meta-analysis of Neurostimulation for Painful Diabetic Neuropathy. Diabetes Care 2022;45:2466 –2475
Duarte et al. (1) reported the results of a network meta-analysis (NMA) that analyzes the effects of spinal cord stimulation (SCS) for painful diabetic neuropathy. They concluded that moderate-certainty evidence supports a large benefit in pain relief as a result of high- and low-frequency SCS compared with conventional medical management. This conclusion is misleading. (Source: Diabetes Care)
Source: Diabetes Care - April 26, 2023 Category: Endocrinology Source Type: research
